دورية أكاديمية
Evaluation of MicroScan WalkAway for Determination of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility in Carbapenem-Resistant Gram-Negative Bacilli.
| العنوان: | Evaluation of MicroScan WalkAway for Determination of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility in Carbapenem-Resistant Gram-Negative Bacilli. |
|---|---|
| المؤلفون: | Ito CAS; Division of Microbiology, Universidade Estadual de Ponta Grossa do Paraná, Ponta Grossa, Paraná, Brazil.; Laboratory of Emerging Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil., Bail L; Division of Microbiology, Universidade Estadual de Ponta Grossa do Paraná, Ponta Grossa, Paraná, Brazil.; Laboratory of Emerging Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil., Arend LNVS; Laboratory of Emerging Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil.; Laboratório Central do Estado do Paraná-LACEN, Curitiba, Paraná, Brazil., Silva KO; Beckman Coulter, Barueri, São Paulo, Brazil., Michelotto SS; LANAC, Curitiba, Paraná, Brazil., Nogueira KDS; Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, Paraná, Brazil.; Basic Pathology Department, Universidade Federal do Paraná, Curitiba, Paraná, Brazil., Tuon FF; Laboratory of Emerging Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil. |
| المصدر: | Journal of clinical microbiology [J Clin Microbiol] 2021 Nov 18; Vol. 59 (12), pp. e0153621. Date of Electronic Publication: 2021 Sep 29. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 7505564 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-660X (Electronic) Linking ISSN: 00951137 NLM ISO Abbreviation: J Clin Microbiol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Washington, American Society for Microbiology. |
| مواضيع طبية MeSH: | Carbapenems* , Ceftazidime*/pharmacology, Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Azabicyclo Compounds ; Cephalosporins/pharmacology ; Drug Combinations ; Humans ; Microbial Sensitivity Tests ; Pseudomonas aeruginosa ; Tazobactam/pharmacology |
| مستخلص: | We evaluated the performance of ceftazidime-avibactam and ceftolozane-tazobactam MicroScan Neg multidrug-resistant MIC 1 (NMR1) panel for clinical carbapenem-nonsusceptible Gram-negative bacilli isolates. We evaluated 212 clinically significant carbapenem-nonsusceptible Gram-negative bacilli (139 Pseudomonas aeruginosa and 73 KPC-producing Enterobacterales ) from 71 Brazilian hospitals (2013 to 2020). Ceftazidime-avibactam and ceftolozane-tazobactam MICs from the panel were compared with a broth microdilution (BMD) test as the reference method. Essential agreement (EA) and categorical agreement (CA) were assessed. For P. aeruginosa, antimicrobial susceptibility testing error rates were calculated using the error-rate bound method. Discrepancies were initially observed with 11 isolates; 4 resolved after retesting, 2 in favor of the NMR1 and 2 in favor of the BMD method. The ceftazidime-avibactam EA (overall and evaluable) was 100% for P. aeruginosa and Enterobacterales. The CA was 100% for Enterobacterales and 98.6% for P. aeruginosa. The ceftolozane-tazobactam EA was 98.6% and 100% (overall and evaluable, respectively), and the CA was 96.4% for P. aeruginosa. For ceftazidime/avibactam, no very major error (VME) was found, and the major error (ME) rate was 4.2% (2/48). For ceftolozane-tazobactam and P. aeruginosa, using the CLSI breakpoints, the minor error (mE) was 11.4%, and no VME or ME was found. While using EUCAST breakpoints, the VME was 11.4% with no ME. The mE becomes ME or VME in the absence of the intermediate category. All categorical errors were also within 1 log of MIC variation, and the adjusted error rate for CLSI/EUCAST was 0% (0/212). The NMR1 panel is an option to test ceftazidime-avibactam for KPC-producing Enterobacterales and carbapenem-nonsusceptible P. aeruginosa. When a MIC of 4 mg/liter for ceftolozane-tazobactam is obtained using this method, an alert could be created, and the results could be confirmed by an alternative method. |
| References: | Braz J Infect Dis. 2020 Mar - Apr;24(2):96-103. (PMID: 32360070) J Antimicrob Chemother. 2019 Mar 1;74(3):633-638. (PMID: 30534964) Infection. 2018 Apr;46(2):165-181. (PMID: 29110143) Clin Infect Dis. 2021 Dec 6;73(11):e4521-e4530. (PMID: 32990319) J Clin Microbiol. 2021 Feb 18;59(3):. (PMID: 33268536) J Appl Microbiol. 2020 Oct;129(4):806-822. (PMID: 32418295) J Clin Microbiol. 2018 Mar 26;56(4):. (PMID: 29367292) J Clin Microbiol. 2021 Nov 18;59(12):e0021321. (PMID: 34550809) Int J Antimicrob Agents. 2013 Oct;42(4):352-6. (PMID: 23988718) Infect Dis Rep. 2017 Mar 30;9(1):6839. (PMID: 28458798) Clin Microbiol Rev. 2020 Nov 11;34(1):. (PMID: 33177185) Curr Infect Dis Rep. 2020 Jan 13;22(1):1. (PMID: 31933158) Int J Mol Sci. 2020 Dec 06;21(23):. (PMID: 33291334) J Glob Antimicrob Resist. 2020 Mar;20:334-338. (PMID: 31568882) Curr Opin Infect Dis. 2019 Dec;32(6):609-616. (PMID: 31567571) Clin Microbiol Infect. 2013 Feb;19(2):E59-71. (PMID: 23210931) |
| فهرسة مساهمة: | Keywords: Gram-negative bacilli; carbapenemase; ceftazidime-avibactam; ceftolozane-tazobactam; susceptibility tests |
| المشرفين على المادة: | 0 (Anti-Bacterial Agents) 0 (Azabicyclo Compounds) 0 (Carbapenems) 0 (Cephalosporins) 0 (Drug Combinations) 0 (avibactam, ceftazidime drug combination) 37A4IES95Q (ceftolozane) 9M416Z9QNR (Ceftazidime) SE10G96M8W (Tazobactam) |
| تواريخ الأحداث: | Date Created: 20210929 Date Completed: 20211203 Latest Revision: 20240404 |
| رمز التحديث: | 20240404 |
| مُعرف محوري في PubMed: | PMC8601251 |
| DOI: | 10.1128/JCM.01536-21 |
| PMID: | 34586889 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1098-660X |
|---|---|
| DOI: | 10.1128/JCM.01536-21 |